← Back to Search

Arm 2 (Digital Intervention) for Cancer

N/A

Recruiting

Led By Walter Stadler

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

for prostate cancer patients: 2 or more increasing prostate specific antigen (PSA) values i the 6 months prior to visit

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years from randomization

Awards & highlights

Study Summary

This trial aims to test different ways of reaching out to underrepresented minorities, specifically African Americans, and see how it affects their enrollment in early phase cancer treatment trials. Both patients and healthcare providers will be

Who is the study for?

This trial is for African American adults who are scheduled for new or follow-up oncology appointments at the study site. It includes those with a recent biopsy or imaging, prostate cancer patients with rising PSA levels, and others identified by researchers as likely needing treatment changes.Check my eligibility

What is being tested?

The study is testing whether digital interventions and community outreach can increase enrollment of underrepresented minorities in early phase cancer clinical trials. Participants will either receive these novel outreach methods or no intervention.See study design

What are the potential side effects?

Since this trial focuses on outreach methods rather than medical treatments, there are no direct physical side effects expected from participating in the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My PSA levels have been rising over the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years from randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years from randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years from randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of patients that enroll to early phase cancer treatment clinical trials.

Secondary outcome measures

Number of successfully completed outreach efforts

Percent change in number of African Americans that enroll to cancer clinical trials

Percentage of patients that enroll to early phase cancer treatment clinical trials post intervention.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Arm 3 (Digital Intervention + Community Outreach)Experimental Treatment2 Interventions

Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. They will also be invited to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial. Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

Group II: Arm 2 (Digital Intervention)Experimental Treatment1 Intervention

Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

Group III: Arm 1 (No Intervention)Active Control1 Intervention

Patient participants in this arm will receive no intervention but will be approached by their providers for participation in treatment clinical trials as per the usual methods. Provider participants will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,004 Previous Clinical Trials

819,597 Total Patients Enrolled

Stand Up To CancerOTHER

51 Previous Clinical Trials

40,114 Total Patients Enrolled

Walter StadlerPrincipal InvestigatorUniversity of Chicago

7 Previous Clinical Trials

621 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still eligible to participate in this ongoing research?

"According to the information available on clinicaltrials.gov, this trial is currently in the active recruitment phase. The initial posting of this clinical trial was made on October 23rd, 2023, and it underwent its latest revision on January 2nd, 2024."

Answered by AI

What is the current number of individuals being recruited for participation in this clinical trial?

"Indeed, the information available on clinicaltrials.gov indicates that this trial is currently in search of eligible participants. The initial posting for the clinical trial was made on October 23, 2023 and it was last updated on January 2, 2024. This study aims to recruit a total of 180 patients from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

2023. "Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05886764.